Enfuvirtide: A fusion inhibitor for the treatment of HIV infection

Medicine & Life Sciences

• Enfuvirtide 100%
• HIV Infections 55%
• HIV-1 20%
• Anti-Retroviral Agents 16%
• Peptide Hydrolases 14%
• Therapeutics 10%
• Injection Site Reaction 7%
• Clinical Trials 7%
• Cell Fusion 6%
• RNA-Directed DNA Polymerase 6%
• Lipase 6%
• Amylases 6%
• Eosinophilia 6%
• Peripheral Nervous System Diseases 6%
• Creatine Kinase 6%
• Sleep Initiation and Maintenance Disorders 6%
• Transferases 5%
• Aspartate Aminotransferases 5%
• United States Food and Drug Administration 5%
• Congresses 5%
• Alanine Transaminase 5%
• Social Adjustment 5%
• Drug Resistance 5%
• Blood Proteins 5%
• Half-Life 5%
• Nausea 5%
• MEDLINE 5%
• Child 4%
• Vomiting 4%
• Headache 4%
• Fatigue 4%
• Anemia 4%
• Acquired Immunodeficiency Syndrome 4%
• Diarrhea 4%
• Fever 4%
• Body Weight 4%
• HIV 3%
• Viruses 3%
• In Vitro Techniques 2%
• Pharmaceutical Preparations 2%